Skip to content
Open access

Imaging T-cell dynamics in tumors using [18F]F-AraG PET: a Phase 1 study with STING agonist and PD-1 blockade therapy

Oct 2026 · npj Imaging · 0 citations

TL;DR

Findings support further clinical application of F-AraG PET to visualize T-cell dynamics and to assess immunomodulatory effects of (immune)therapies.

Abstract

Immunotherapies have revolutionized cancer treatment, yet tools for monitoring immune activation in vivo remain limited. This pilot study investigates the potential of [ 18 F]F-AraG PET to visualize activated T-cell dynamics and to assess the immunomodulatory effects of the STING agonist GSK3745417 ± PD-1 inhibitor dostarlimab. Four patients with advanced solid tumors underwent Baseline [ 18 F]FDG PET/CT, tumor biopsy and [ 18 F]F-AraG PET. GSK3745417 was administered intravenously weekly, with triweekly dostarlimab initiated in Week 2. On-treatment [ 18 F]F-AraG PET scans were acquired at Week 1 and Week 6, accompanied by a biopsy in Week 6. [ 18 F]F-AraG uptake in tumors and organs was quantified using peak tissue-to-plasma ratios. Biopsies were analyzed with imaging mass cytometry, histopathology and multiplex immunohistochemistry (mIHC). Best overall responses were partial response (patient A), stable disease (C/D) and progressive disease (B). Patient A demonstrated the highest Baseline [ 18 F]F-AraG uptake in tumors and stronger increase than other patients at Week 1. Changes in [¹⁸F]F‑AraG uptake from Baseline to Week 6 showed concordance with changes in CD8⁺Ki67⁺TIM3⁻ T‑cell density in the three evaluable patients. mIHC supported the contribution of T-cells to the [ 18 F]F-AraG PET signal. These findings support further clinical application of [ 18 F]F-AraG PET to visualize T-cell dynamics and to assess immunomodulatory effects of (immune)therapies.

Read PDF

Similar papers

Open access Oct 2026

PET pharmacokinetics of [¹⁸F]F-AraG as a marker of T cell activation during immunotherapy with a STING agonist with and without anti-PD-1

There is an urgent need for clinical biomarkers to monitor the mechanistic efficacy of immunotherapy in oncology. The [18F]F-AraG tracer, developed to image activated T cells, may provide the means to establish such a biomarker. This study extends previously reported pharmacokinetic findings in untreated NSCLC across a...

J. E. E. Pouw, M. Stavenga, J. Wijngaarden et al. · 0 citations
Oct 2026

Integrated [68Ga]Ga-FAPI-7ND PET/CT and stromal profiling of immunocompetent syngeneic tumor models for FAP-targeted radionuclide therapy.

In 4 T1 tumors, [177Lu]Lu-FAPI-7ND showed antitumor activity accompanied by immune microenvironmental alterations, supporting integrated model selection for immunocompetent FAP-RNT studies.

Hui-Jie Li, Yu-Ling Zhang, Xin-Yin Ren et al. · 0 citations
Oct 2026

[18F]F-AraG PET Imaging of Immunometabolic Activity in Individuals Without Malignancy.

[18F]F-AraG is a clinical-stage PET tracer in immuno-oncology that accumulates in activated T cells and tissues with high mitochondrial biogenesis. Characterizing its distribution in individuals without malignancy is essential for interpreting immunometabolic states relevant to cancer biology. Methods: Twenty adults wi...

H. Chae, Tomomi W. Nobashi, Uttam M. Shrestha et al. · 0 citations
Oct 2026

FAP-targeted [177Lu]Lu-FAP-2286 radioligand therapy synergizes with the STING agonist diABZI to enhance antitumor immunity in lung cancer.

This combination reshapes the tumor immune microenvironment via enhanced CD8+ T-cell infiltration and IFN-β-mediated immune activation and IFN-β-mediated immune activation, offering a translatable strategy for patients with advanced FAP-expressing lung cancer.

Jia-Hao Xie, Yi-Jin Zou, Da-Zhi Shi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.